Compare Cytokinetics Inc (CYTK) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Etsy Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Etsy Inc trades at $83.3 (market cap $7.88B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Etsy Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | ETSY | |
|---|---|---|
Market Cap | $11.12B | $7.88B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $83.06 |
52-Week Low | $33.23 | $44.05 |
Enterprise Value | $11.59B | $9.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
ETSY trades at $80.53, down 0.64% today, with strong technical momentum as the stock has rallied 40% over the past three months. The company shows mixed fundamentals with revenue stabilizing around $2.9B but net income declining to $163M in 2025. Recent earnings beats and positive analyst sentiment (48.9% buy ratings) support the bullish technical outlook, though valuation metrics remain elevated with a P/E of 30.85.
The outlook remains cautiously optimistic with AI-driven marketplace improvements and seller tools driving growth potential. Key risks include active buyer declines, competitive pressures from larger e-commerce players, and high debt levels. The stock trades near analyst consensus targets, suggesting limited near-term upside from current levels despite positive momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
